Pediatrix Medical Group
American physician-led national medical group
MD NYSE
SEC CIK 893949
Follow Pediatrix Medical
Weekly email: filings, results
Revenue, last quarter
$501.4M
+1.7% vs same quarter last year
Net income
$47M
−34.5% vs same quarter last year
EPS, diluted
$0.59
−29.8% vs same quarter last year
Operating cash flow
$117.3M
−14.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.9B | $165.4M |
| FY24 | $2B | −$99.1M |
| FY23 | $2B | −$60.4M |
| FY22 | $2B | $66.3M |
| FY21 | $1.9B | $131M |
| FY20 | $1.7B | −$796.5M |
| FY19 | $1.8B | −$1.5B |
| FY18 | $1.7B | $268.6M |
| FY17 | $3.3B | $320.4M |
| FY16 | $3.2B | $324.9M |
| FY15 | - | $336.3M |
| FY14 | - | $317.3M |
| FY13 | - | $280.5M |
| FY12 | - | $240.9M |
| FY11 | - | $218M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 10.9% | 8.6% |
| FY24 | −3.4% | −4.9% |
| FY23 | 0.4% | −3% |
| FY22 | 8.8% | 3.4% |
| FY21 | 10.6% | 6.9% |
| FY20 | 5.7% | −45.9% |
| FY19 | 9.7% | −84.2% |
| FY18 | 14.4% | 15.6% |
| FY17 | 14% | 9.8% |
| FY16 | 18% | 10.2% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $86.7M |
| FY24 | $1.7M |
| FY23 | $919K |
| FY22 | $88.5M |
| FY21 | $4.7M |
| FY20 | $8.5M |
| FY19 | $145.3M |
| FY18 | $302.2M |
| FY17 | $70.2M |
| FY16 | $61.8M |
| FY15 | $235.1M |
| FY14 | $488.4M |
| FY13 | $51.9M |
| FY12 | - |
| FY11 | - |
- Pediatrix Medical
- Healthcare median
Show the numbers
| Year | Pediatrix Medical | Healthcare median |
|---|---|---|
| FY25 | 8.6% | −30.6% |
| FY24 | −4.9% | −47% |
| FY23 | −3% | −58% |
| FY22 | 3.4% | −80.4% |
| FY21 | 6.9% | −71.9% |
| FY20 | −45.9% | −62.2% |
| FY19 | −84.2% | −46.3% |
| FY18 | 15.6% | −49.6% |
| FY17 | 9.8% | −45.9% |
| FY16 | 10.2% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |